1. Bayer and Janssen, J&J’s pharmaceutical business, filed a patent lawsuit against Indian pharmaceutical company USV Private Limited on Sept. 9 over Xarelto, a blood thinner drug that was approved by the FDA in early 2017. The two companies accuse USV of a patent infringement because of USV’s July 2022 drug application that contains the Xarelto generic rivaroxaban.
2. In two Australian class-action lawsuits, J&J settled for $300 million in the continent’s largest settlement for a product liability class-action case, The Guardian reported Sept. 11. Thousands of women joined the case after reporting chronic pain, incontinence and painful sexual intercourse from J&J’s pelvic mesh implants. This was the second class-action suit concerning the company’s pelvic mesh products, which are used for pelvic organ prolapse.
3. Two days after the company stopped the global sale of talc-based baby powder, J&J’s business LTL Management said in court documents that bankruptcy for the subsidiary was the only option because of the mountain of talc lawsuits, which currently surpass 40,000.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
